Global Information
회사소개 | 문의 | 비교리스트

Shionogi & Co., Ltd. : 제품 파이프라인 리뷰

Shionogi & Co Ltd - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 251722
페이지 정보 영문 88 Pages
가격
US $ 1,500 ₩ 1,806,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,612,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,418,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Shionogi & Co., Ltd. : 제품 파이프라인 리뷰 Shionogi & Co Ltd - Product Pipeline Review - 2016
발행일 : 2016년 12월 페이지 정보 : 영문 88 Pages

Shionogi & Co., Ltd.는 순환기계, 대사계, 감염증, 면역계, 암성 통증 등 영역의 의약제품, 진단법, 기타 관련 제품을 제조판매하고 있는 제약회사입니다. Shionogi & Co., Ltd.의 핵심 의약품 사업은 처방전약, OTC 의약품, 진단약으로 구성되어 있습니다.

Shionogi & Co., Ltd.의 치료제 개발 파이프라인 현황과 각 개발 단계의 비교 분석, 약제 표적, 작용기서, 투여 경로, 분자 유형별 치료제 평가, 최신 기업 뉴스 및 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 정리하여 전해드립니다.

Shionogi & Co., Ltd.의 기본 정보

  • Shionogi & Co., Ltd.의 개요
  • 주요 정보
  • 기업 정보

Shionogi & Co., Ltd. : R&D 개요

  • 주요 치료 범위

Shionogi & Co., Ltd. : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단일요법 제품
  • 파트너 제품
    • 파트너 제품/병용요법 모달리티
  • 아웃 라이선스 제품
    • 아웃 라이선스 제품/병용요법 모달리티

Shionogi & Co., Ltd. : 파이프라인 제품 개요

  • 최종 단계 파이프라인 제품
    • 등록전 제품/병용요법 모달리티
    • 제III상 제품/병용요법 모달리티
  • 임상시험 단계 파이프라인 제품
    • 제II상 제품/병용요법 모달리티
    • 제I상 제품/병용요법 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 단계 제품/병용요법 모달리티
    • Discovery 제품/병용요법 모달리티

Shionogi & Co., Ltd. : 약제 개요

Shionogi & Co., Ltd. : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 유형별
  • 작용기서별

Shionogi & Co., Ltd. : 최근 파이프라인 동향

Shionogi & Co., Ltd. : 휴지중인 프로젝트

Shionogi & Co., Ltd. : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품의 개요
    • doripenem
    • lusutrombopag
    • S-234462
    • S-288310
    • S-444823
    • S-488410
    • S-5751
    • S-777469
    • S-8510
    • teceleukin
    • velneperit

Shionogi & Co., Ltd. : 기업 발표

Shionogi & Co., Ltd. : 본사와 자회사 소재지

Shionogi & Co., Ltd. : 주요 제조설비

부록

도표

KSA 16.01.25

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Shionogi & Co Ltd - Product Pipeline Review - 2016', provides an overview of the Shionogi & Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Shionogi & Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Shionogi & Co Ltd
  • The report provides overview of Shionogi & Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Shionogi & Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Shionogi & Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Shionogi & Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Shionogi & Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Shionogi & Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Shionogi & Co Ltd Snapshot
    • Shionogi & Co Ltd Overview
    • Key Facts
  • Shionogi & Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Shionogi & Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Shionogi & Co Ltd - Pipeline Products Glance
    • Shionogi & Co Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Shionogi & Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shionogi & Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Shionogi & Co Ltd - Drug Profiles
    • A-2NTX - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMG-0101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • asapiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cefiderocol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doripenem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lusutrombopag - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PcrV for Resistant Pseudomonas aeruginosa Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naldemedine tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ospemifene - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • oxycodone hydrochloride ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Agonize NPR1 and NPR2 for Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rovatirelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-010887 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-033188 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-117957 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-120083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-222611 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-237648 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-488210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-588410 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-600918 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-707106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize P2X3 Receptor for Neuropathic Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block TRPV4 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Tuberculosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize CB2 for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize NPY5R for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Penicillin Binding Protein for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SR-0379 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • STAGR-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • standardized mite (Dermatophagoides farinae + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Shionogi & Co Ltd - Pipeline Analysis
    • Shionogi & Co Ltd - Pipeline Products by Target
    • Shionogi & Co Ltd - Pipeline Products by Route of Administration
    • Shionogi & Co Ltd - Pipeline Products by Molecule Type
    • Shionogi & Co Ltd - Pipeline Products by Mechanism of Action
  • Shionogi & Co Ltd - Dormant Projects
  • Shionogi & Co Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ADX-415
      • capravirine
      • doripenem
      • GSK-364735
      • GW-810781
      • lisdexamfetamine dimesylate
      • lusutrombopag
      • S-234462
      • S-288310
      • S-444823
      • S-488410
      • S-5751
      • S-646240
      • S-777469
      • S-8510
      • teceleukin
      • varespladib sodium
      • velneperit
  • Shionogi & Co Ltd - Company Statement
  • Shionogi & Co Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shionogi & Co Ltd, Key Facts
  • Shionogi & Co Ltd - Pipeline by Indication, 2016
  • Shionogi & Co Ltd - Pipeline by Stage of Development, 2016
  • Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016
  • Shionogi & Co Ltd - Combination Treatment Modalities in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Shionogi & Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Shionogi & Co Ltd - Pre-Registration, 2016
  • Shionogi & Co Ltd - Phase III, 2016
  • Shionogi & Co Ltd - Phase II, 2016
  • Shionogi & Co Ltd - Phase I, 2016
  • Shionogi & Co Ltd - Preclinical, 2016
  • Shionogi & Co Ltd - Discovery, 2016
  • Shionogi & Co Ltd - Pipeline by Target, 2016
  • Shionogi & Co Ltd - Pipeline by Route of Administration, 2016
  • Shionogi & Co Ltd - Pipeline by Molecule Type, 2016
  • Shionogi & Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Shionogi & Co Ltd - Dormant Developmental Projects,2016
  • Shionogi & Co Ltd - Discontinued Pipeline Products, 2016
  • Shionogi & Co Ltd, Other Locations
  • Shionogi & Co Ltd, Subsidiaries

List of Figures

  • Shionogi & Co Ltd - Pipeline by Top 10 Indication, 2016
  • Shionogi & Co Ltd - Pipeline by Stage of Development, 2016
  • Shionogi & Co Ltd - Monotherapy Products in Pipeline, 2016
  • Shionogi & Co Ltd - Partnered Products in Pipeline, 2016
  • Shionogi & Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Shionogi & Co Ltd - Pipeline by Top 10 Target, 2016
  • Shionogi & Co Ltd - Pipeline by Route of Administration, 2016
  • Shionogi & Co Ltd - Pipeline by Molecule Type, 2016
  • Shionogi & Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top
전화 문의
F A Q